AAE has published a Policy Paper on Access to PrEP in the EU/EEA Countries.
Pre-exposure prophylaxis (PrEP) with oral antiretroviral medication is a highly effective and evidence-based HIV prevention method. Despite its high clinical efficacy, efforts to expand the use of oral PrEP in EU/EEA countries have not fully realised its potential as part of combination prevention due to a variety of factors related to accessibility, affordability, and acceptability.
The design, the provision, and the implementation of PrEP and PrEP-related services are not
purely medical or public health matters, and their success depends on the level of fulfilment of human rights obligations by states.
This Policy Paper is based on the findings of the Rapid Assessment on Access to PrEP in the EU/EEA conducted by AAE in 2022 and includes policy recommendations to all EU/EEA member states.
